2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2647

Effects of Pain Expectations On Neuromuscular Control of the Spine in Patients with Chronic Low Back Pain and Healthy Participants
Abstract Number: 2203

Effects of Reclassification Using the American College of Rheumatology Criteria On a Large cohort Sjögren’s Syndrome Patients
Abstract Number: 1075

Effects of siRNA Depletion of Interferon Regulatory Factor 5 On Pro-Inflammatory Cytokine Production and IgG Secretion by Primary Human Immune Cells in Response to TLR7/8 Stimulation
Abstract Number: 1238

Effects of Stress On Clinical Presentation of Patients with Early Rheumatoid Arthritis
Abstract Number: 1109

Effects of Strontium Ranelate On Hand Osteoarthritis – Analysis of Data From the Sekoia Trial
Abstract Number: 254

Effects of Strontium Ranelate On Knee Osteoarthritis Pain: A Responder Analysis
Abstract Number: 1340

Effects of Subcutaneous Abatacept or Adalimumab On Remission and Associated Changes in Physical Function and Radiographic Outcomes: One Year Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Abstract Number: 1290

Effects of Tofacitinib On Lipid Profiles and Cholesterol and Lipoprotein Kinetics in Patients with Rheumatoid Arthritis
Abstract Number: 1283

Effects of Tofacitinib On Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis Receiving Stable-Dose Methotrexate: Results of Two Phase 3 Studies
Abstract Number: 642

Effects of Treatment On the Expression of CCL2 and CXCL10 in Systemic Lupus Erythematosus Patients
Abstract Number: 476

Effects of Vitamin D Repletion and Maintenance Therapy On Clinical Indicators of Disease Activity in Rheumatoid Arthritis
Abstract Number: 539

Efficacy and Safety of Adalimumab for the Treatment of Peripheral Arthritis in Spondyloarthritis Patients without Ankylosing Spondylitis or Psoriatic Arthritis
Abstract Number: 750

Efficacy and Safety of Canakinumab in Adults with Colchicine Resistant Familial Mediterranean Fever
Abstract Number: 759

Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis and Fever: Results From Two Pivotal Phase 3 Trials
Abstract Number: 748

Efficacy and Safety of Canakinumab in Patients with Cryopyrin Associated Periodic Syndrome: Results From Meta-Analysis of 5 Studies

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].